Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time

Elan Corporation, plc (ELN)

Q3 2007 Earnings Call

October 25, 2007 8:30 am ET

Executives

Chris Burns - IR

Kelly Martin - President and CEO

Shane Cooke - EVP and CFO

Lars Ekman - EVP of R&D

Analysts

Jack Gorman - Davy

Ian Hunter - Goodbody Stockbrokers

Orla Hartford - NCB Stockbrokers

Corey Davis - Natixis Bleichroeder

Bill Tanner - Leerink Swann

Rich Silver - Lehman Brothers

Walter Branson - Regiment Capital

Ian Anderson - Cowen & Company

Presentation

Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Elan Pharmaceutical Corporation Third Quarter 2007 Financial Results Conference Call. During the presentation, all participants will be in a listen-only mode. Afterwards, we will conduct a question-and-answer session. (Operator Instructions). As a reminder, this conference is being recorded, Thursday, October 25th. Your speaker for today is Chris Burns, Investor Relations.

I will now like to turn the conference over to Chris Burns. Please go ahead, sir.

Chris Burns

Hello, everyone. Welcome to Elan’s third quarter 2007 financial results call. I hope you’ve had a chance to review our press release. If not, we encourage you to go to our website at www.elan.com, where you'll find it.

Joining me on today's call will be President and CEO, Kelly Martin; Executive Vice President and CFO, Shane Cooke; and Executive Vice President of Research and Development, Dr. Lars Ekman who is joining us from Europe. Today, we’ll take you through our financial results and provide an R&D and business update.

Before we begin with Kelly’s remarks, I’ll review our Safe Harbor statement. Let me remind you that today’s call will contain forward-looking statements about Elan’s financial condition, results of operations, business prospects, and products and research. These forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those described or projected. A list of these risks and uncertainties is included in our third quarter financial results' press release which was issued this morning and in our 2006 annual report on Form 20-F and our Form 6-K filed with or furnished to with the Securities and Exchange Commission.

Elan assumes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. In addition, today’s conference call webcast will include certain financial measures such as EBITDA; Earnings Before Interest, Taxes, Depreciation, and Amortization; and adjusted EBITDA, EBITDA plus or minus share-based compensation, net gains or losses on divestment businesses, other net gains and charges, net investment gains or losses and net charges on debt retirement. These financial measures are non-GAAP financial measures under Securities and Exchange Commission rules. A reconciliation of these non-GAAP financial measures and most directly comparable GAAP measures are included in today’s press release.

Now, I’ll turn the call over to Kelly Martin.

Kelly Martin

Thank you, Chris, and we appreciate everybody joining us today. On behalf of Kyran McLaughlin and myself, the rest of management team and the rest of the Board, we would like to share with you the results and some comments from our last quarter. I’ll make a few comments before I turn things over to Shane Cooke, who is also joining me on this call, our CFO. And Dr. Lars Ekman, the President of R&D is also on the call and he will make some comments after Shane.

Now before turning it over to Shane, I’ll just like to go through a number of things. With regards to this past quarter, I believe we have demonstrated the continued execution and have delivered some tangible results in three key areas. Broadly, financially, our revenue was up over 40%. Our operating expenses were down 3%. The net loss was reduced by 25% and as you’ll hear from Shane, the adjusted EBITDA was reduced by over 65%.

In Tysabri, we continue to have enormous confidence in Tysabri in MS as well as further indications GI, oncology and perhaps others down the road. We continue to work very diligently with our partner Biogen on maximizing the value of this asset as we move forward in its evolution. And lastly, with regards to Tysabri, based on its efficacy, we believe there is very significant continued upside in the MS indication within the US, Europe and rest of the world markets.

The third area of progress over the third quarter is our continued focus and advancement in the Alzheimer’s space with regard to clinical activity. We continue to make progress across the Board. With our partner Transition Therapeutics and the compound ELND-005, we have announced that we will be starting our initial Phase II trial sometime over the next few months.

In immunotherapy with our partner Wyeth, we continue to broaden the number of programs in immunotherapy, deepen our knowledge and accelerate their advancements both individually and collectively. Importantly, AAB-001, is the lead program in that portfolio of immunotherapeutic activity, Dr. Ekman will provide a very specific update on this clinical program during his remarks.

With that, I am going to turn it to our Chief Financial Officer, Shane Cooke and he will walk you through the quarter’s results in our financial arena. Shane?

Shane Cooke

Thanks Kelly and good morning and good afternoon to everybody. My prepared remarks will focus on the overall results for the quarter, together with an update on the performance of Tysabri and our expectations for the remainder of 2007.

Before going into a more detailed presentation, I would like to firstly highlight four key aspects of this quarter's financial results. One, we continue to see an improvement in operating margins with revenues increasing at a much faster space than operating costs, which results in a 25% reduction in net losses and a 66% reduction in adjusted EBITDA losses.

Read the rest of this transcript for free on seekingalpha.com